Form 4: Entrada Therapeutics Director Peter S. Kim Increases Stake in Company

Director Peter S. Kim of Entrada Therapeutics, Inc. [TRDA] has been actively purchasing common stock, increasing his holdings over several transactions in March 2024.

Summary

• Peter S. Kim, a director at Entrada Therapeutics, Inc., has been buying shares of the company's common stock.
• On March 22, 2024, he purchased 3,118 shares at a weighted average price of $13.759 per share, increasing his direct holdings to 52,894 shares.
• He continued purchasing on March 25, 2024, acquiring 3,180 shares at a weighted average price of $13.356, bringing his total to 56,074 shares.
• On March 26, 2024, Kim bought an additional 2,750 shares at a weighted average price of $13.6397, resulting in a total of 58,824 shares held directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the director's increased investment in the company, suggesting confidence. However, it's a single data point and requires further context.

Positives

• The director's purchases could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider buying is often monitored by investors as an indicator of management's confidence in the company's prospects. It can be a positive sign, but should be considered alongside other factors.

Stakeholder Impact

• Shareholders may view the director's stock purchases as a positive signal.

Key Dates